Evidence Feed

About

Diagnostics

New

Top genes

FAQ

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CYAD-211

ⁱ

Other names: CYAD-211, shRNA-based allogeneic BCMA CAR-T

News alerts, weekly reports and conference planners

Associations

News

Trials

Company:

Celyad Oncology

Drug class:

BCMA-targeted CAR-T immunotherapy

Related drugs:

‹

idecabtagene vicleucel (2)

CB-011 (2)

ciltacabtagene autoleucel (2)

equecabtagene autoleucel (1)

PBCAR269A (1)

bb21217 (1)

AUTO2 (0)

Autologous CAR-T cells (0)

BCMA CAR-T cell therapy (0)

BCMA targeted CAR T (0)

BCMA targeted CAR T-cells (0)

BCMA-BCL2L1-CART (0)

BCMA-PD1-CART Cells (0)

BMS-986354 (0)

CART-138/BCMA/19/more (0)

CART-BCMA/CS1 (0)

CD19/BCMA targeted CAR T-cells (0)

anti-BCMA CAR-T cells (0)

ARI0002h (0)

PHE885 (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

JCARH125 (0)

senl_BCMA (0)

CT053 (0)